TY - JOUR T1 - Are commercial antibody assays substantially underestimating SARS-CoV-2 ever infection? An analysis on a population-based sample in a high exposure setting JF - medRxiv DO - 10.1101/2020.12.14.20248163 SP - 2020.12.14.20248163 AU - Gheyath K. Nasrallah AU - Soha R. Dargham AU - Farah Shurrab AU - Duaa W. Al-Sadeq AU - Hadeel Al-Jighefee AU - Hiam Chemaitelly AU - Zaina Al Kanaani AU - Abdullatif Al Khal AU - Einas Al Kuwari AU - Peter Coyle AU - Andrew Jeremijenko AU - Anvar Hassan Kaleeckal AU - Ali Nizar Latif AU - Riyazuddin Mohammad Shaik AU - Hanan F. Abdul Rahim AU - Hadi M. Yassine AU - Mohamed G. Al Kuwari AU - Hamda Qotba AU - Hamad Eid Al Romaihi AU - Patrick Tang AU - Roberto Bertollini AU - Mohamed Al-Thani AU - Asmaa A. Althani AU - Laith J. Abu-Raddad Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/12/14/2020.12.14.20248163.abstract N2 - Background Performance of three automated commercial serological IgG-based assays was investigated for assessing SARS-CoV-2 ever (past or current) infection in a population-based sample in a high exposure setting.Methods PCR and serological testing was performed on 394 individuals.Results SARS-CoV-2-IgG seroprevalence was 42.9% (95% CI 38.1%-47.8%), 40.6% (95% CI 35.9%-45.5%), and 42.4% (95% CI 37.6%-47.3%) using the CL-900i, VidasIII, and Elecsys assays, respectively. Between the three assays, overall, positive, and negative percent agreements ranged between 93.2%-95.7%, 89.3%-92.8%, and 93.8%-97.8%, respectively; Cohen kappa statistic ranged from 0.86-0.91; and 35 specimens (8.9%) showed discordant results. Among all individuals, 12.5% (95% CI 9.6%-16.1%) had current infection, as assessed by PCR. Of these, only 34.7% (95% CI 22.9%-48.7%) were seropositive by at least one assay. A total of 216 individuals (54.8%; 95% CI 49.9%-59.7%) had evidence of ever infection using antibody testing and/or PCR during or prior to this study. Of these, only 78.2%, 74.1%, and 77.3% were seropositive in the CL-900i, VidasIII, and Elecsys assays, respectively.Conclusions All three assays had comparable performance and excellent agreement, but missed at least 20% of individuals with past or current infection. Commercial antibody assays can substantially underestimate ever infection, more so when infection rates are high.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors are grateful for support provided by Qatar University, Ministry of Public Health, Hamad Medical Corporation, and the Biomedical Research Program and the Biostatistics, Epidemiology, and Biomathematics Research Core, both at Weill Cornell Medicine-Qatar. Part of this work was made possible by grant No. RRC-2-032 from the Qatar National Research Fund (a member of Qatar Foundation) given to GKN. Finally, we would like to thank the BioMerieux Middle East Regional Office and their distributor in Qatar for providing us with the VidasIII reagent as in-kind support for this project. The statements made herein are solely the responsibility of the authors.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The research work was approved by the ethics review boards at HMC, QU, and Weill Cornell Medicine-QatarAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data are available within the manuscript. ER -